Stratégies thérapeutiques du cancer de la prostate, résistant à la castration

Th Bessede; P. Beuzeboc; F. Bladou; K. Fizazi; P. Mongiat-Artus; A. Villers

doi:10.1016/S1166-7087(11)70015-X

Stratégies thérapeutiques du cancer de la prostate, résistant à la castration

Translated title of the contribution: Strategies in castration-resistant prostate cancer

Th Bessede, P. Beuzeboc, F. Bladou, K. Fizazi, P. Mongiat-Artus, A. Villers

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

according to the circumstances and the time of its occurrence. New therapeutic targets have been determined with basic tumor biology studies. Treatments available or on development are various and range from estrogens to new anti-androgens. Endothelin inhibitors, abiraterone, MDV3100 or RD162 are the most promising examples but they require to enrol patients in therapeutic trials.

Translated title of the contribution	Strategies in castration-resistant prostate cancer
Original language	French
Pages (from-to)	S68-S71
Journal	Progres en Urologie
Volume	21
Issue number	SUPPL. 2
DOIs	https://doi.org/10.1016/S1166-7087(11)70015-X
Publication status	Published - 1 Mar 2011

Access to Document

10.1016/S1166-7087(11)70015-X

Cite this

@article{069cb6eca98c430e96fe2500d697aac4,

title = "Strat{\'e}gies th{\'e}rapeutiques du cancer de la prostate, r{\'e}sistant {\`a} la castration",

abstract = "according to the circumstances and the time of its occurrence. New therapeutic targets have been determined with basic tumor biology studies. Treatments available or on development are various and range from estrogens to new anti-androgens. Endothelin inhibitors, abiraterone, MDV3100 or RD162 are the most promising examples but they require to enrol patients in therapeutic trials.",

keywords = "Abiraterone, Androgen receptor, Castration-resistant, Endothelin, Estrogens",

author = "Th Bessede and P. Beuzeboc and F. Bladou and K. Fizazi and P. Mongiat-Artus and A. Villers",

year = "2011",

month = mar,

day = "1",

doi = "10.1016/S1166-7087(11)70015-X",

language = "Fran{\c c}ais",

volume = "21",

pages = "S68--S71",

journal = "Progres en Urologie",

issn = "1166-7087",

number = "SUPPL. 2",

}

TY - JOUR

T1 - Stratégies thérapeutiques du cancer de la prostate, résistant à la castration

AU - Bessede, Th

AU - Beuzeboc, P.

AU - Bladou, F.

AU - Fizazi, K.

AU - Mongiat-Artus, P.

AU - Villers, A.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - according to the circumstances and the time of its occurrence. New therapeutic targets have been determined with basic tumor biology studies. Treatments available or on development are various and range from estrogens to new anti-androgens. Endothelin inhibitors, abiraterone, MDV3100 or RD162 are the most promising examples but they require to enrol patients in therapeutic trials.

AB - according to the circumstances and the time of its occurrence. New therapeutic targets have been determined with basic tumor biology studies. Treatments available or on development are various and range from estrogens to new anti-androgens. Endothelin inhibitors, abiraterone, MDV3100 or RD162 are the most promising examples but they require to enrol patients in therapeutic trials.

KW - Abiraterone

KW - Androgen receptor

KW - Castration-resistant

KW - Endothelin

KW - Estrogens

UR - http://www.scopus.com/inward/record.url?scp=79952605196&partnerID=8YFLogxK

U2 - 10.1016/S1166-7087(11)70015-X

DO - 10.1016/S1166-7087(11)70015-X

M3 - Article

C2 - 21397833

AN - SCOPUS:79952605196

SN - 1166-7087

VL - 21

SP - S68-S71

JO - Progres en Urologie

JF - Progres en Urologie

IS - SUPPL. 2

ER -

Stratégies thérapeutiques du cancer de la prostate, résistant à la castration

Abstract

Access to Document

Other files and links

Cite this